Skip to main content
Aditya Bardia, MD, Oncology, Boston, MA, Massachusetts General Hospital

AdityaBardiaMD

Oncology • Boston, MA

Attending Physician, Massachusetts General Hospital, Harvard Medical School

Join to view full profile

Dr. Bardia is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Bardia's full profile

Already have an account?

  • Office

    55 Fruit St
    Yawkey 9a, Massachusetts General Hospital Cancer Center
    Boston, MA 02114
    Phone+1 617-724-1074
  • Is this information wrong?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2008 - 2011
  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2005 - 2008
  • All India Institute of Medical Sciences
    All India Institute of Medical SciencesClass of 2003

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2011 - 2025
  • MD State Medical License
    MD State Medical License 2008 - 2012
  • MN State Medical License
    MN State Medical License 2007 - 2008
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances  
    Aditya Bardia, MD, Clinical Cancer Research
  • A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer  
    David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research

Lectures

  • Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). 
    2019 ASCO Annual Meeting - 6/1/2019
  • EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therap... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safe... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • Orserdu (Elacestrant) Approved for Patients with ESR1 Mutations in ER+/HER2- Advanced or Metastatic Breast Cancers
    Orserdu (Elacestrant) Approved for Patients with ESR1 Mutations in ER+/HER2- Advanced or Metastatic Breast CancersFebruary 3rd, 2023
  • Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (Elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
    Stemline Therapeutics, a Subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (Elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast CancerJanuary 30th, 2023
  • Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022
    Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022November 26th, 2022
  • Join now to see all

Professional Memberships

Other Languages

  • Hindi

Hospital Affiliations

Dr. Aditya Bardia, Dr. Aditya Bardia, MD, Dr. A Bardia